Hims & Hers Delivers Huge Growth Despite Stock Drop

Hims & Hers - our best performing pick ever - reported another outstanding quarter and fiscal year. For the year, revenues were up 69%, with Q4 coming in 95% higher than the comparable quarter last year - its fastest growth quarter of the year. The company has a lot of momentum. Monthly revenue per subscriber was up 19% of the year, 38% for the quarter. HIMS ended the year with 2.2 million subscribers, a 45% increase over last year. Yes, I know the stock has plummeted from $70 down to the low $40's, but the $70 number was just market foolishness over GLP hype. The truth is that less than 15% of Hims & Hers business is GLP drugs, and the company grew revenue 43% even taking that out entirely. With my new (and greatly raised) $35 price target, where it trades now is approaching fair value. This is going to be a wild ride, and my plan is to just ride it out. The trajectory should be up - way up - over time. Let your winners ride!

Watch List

WDAY -13.18%
VEEV 12.52%
PSTG -7.13%
INTU 14.19%
CMG 31.78%
RDDT 7.17%
NTNX 17.22%
CRWD 76.14%
SE 19.26%
SNOW 5.28%
APPF 6.95%

Buy List

PINS -37.54%
ASML -25.06%
SEMR -37.55%
TSM -43.44%
ZETA -32.89%
GOOG -51.47%
NYAX -30.39%
MSFT -31.81%
ODD -32.30%
ASR -26.98%
FLYW -44.52%
HRMY -60.41%
YOU -37.20%
ABNB -33.55%
MELI -26.26%
ADBE -45.26%

Hold List

VTEX -17.92%
CELH 49.08%
TOST 16.30%
CPNG -14.83%
HIMS -23.69%
PAYC -21.14%
MNDY 7.35%
GLBE -24.43%
ZS 23.06%
V -7.38%
ADSK -2.06%
NOW -1.85%
FTNT -4.90%
TEAM -8.65%